Fig. 2From: Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation statusPFS and OS. a PFS and OS for the total population; b PFS comparison between two arms; c OS comparison between two arms; d PFS for the resection patients; e OS for the resection patients; f The 2nd PFS. Abbreviations: GC, gemcitabine/carboplatin; PFS, progression-free survival; OS, overall survivalBack to article page